Entera Bio Ltd. Free Cash Flow per Share

Free Cash Flow per Share of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow per Share growth rates and interactive chart. Free cash flow per share. Calculated as operating cash flow minus capital expenditures and divided by the weighted average number of shares outstanding. Free cash flow is the cash flow available to all the investors in a company, including common stockholders, preferred shareholders, and lenders. It is usually used in discounted cash flow models to determine a company's intrinsic value.


Highlights and Quick Summary

  • Free Cash Flow per Share for the quarter ending June 29, 2020 was -0.19 (a 29.97% increase compared to previous quarter)
  • Year-over-year quarterly Free Cash Flow per Share increased by 40.25%
  • Annual Free Cash Flow per Share for 2019 was -0.74 (a -40.52% decrease from previous year)
  • Annual Free Cash Flow per Share for 2018 was -1.24 (a 21.68% increase from previous year)
  • Twelve month Free Cash Flow per Share ending June 29, 2020 was -0.61 (a 13.28% increase compared to previous quarter)
  • Twelve month trailing Free Cash Flow per Share decreased by -9.76% year-over-year
Trailing Free Cash Flow per Share for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-0.61 -0.54 -0.74 -0.67
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow per Share of Entera Bio Ltd.

Most recent Free Cash Flow per Shareof ENTX including historical data for past 10 years.

Interactive Chart of Free Cash Flow per Share of Entera Bio Ltd.

Entera Bio Ltd. Free Cash Flow per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -0.19 -0.15
2019 -0.26 -0.14 -0.18 -0.17 -0.74
2018 -0.15 -0.2 -0.61 -0.56 -1.24
2017 0.0 -1.02

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.